GTx (GTXI) says two Phase III clinicals of Enobosarm will continue after a planned safety review. The company is compiling an "extensive safety database" as clinical trials progress for the company's cancer-related muscle deterioration treatment which was given Fast Track designation by the FDA in January. GTXI plans to file for marketing approval in Q3. Stifel Nicolaus calls the drug a "significant value-creating event."
at MarketWatch.com (May 8, 2012)